Strategic partnerships Leverage CEL-SCI’s recent BIO 2026 collaboration with Saudi Amarox to pursue international co-development, licensing, or distribution agreements in oncology immunotherapy, focusing on head and neck cancer pathways and orphan drug opportunities.

Orphan Drug angle Position Multikine’s FDA Orphan Drug designation for neoadjuvant therapy as a differentiator for potential grants, reimbursement discussions, and accelerated regulatory conversations in markets seeking orphan/rare cancer therapies.

Clinical leadership Engage with CEL-SCI’s Phase 3 findings and IT-MATTERS trial data to target oncologists and hospital systems evaluating neoadjuvant immunotherapies for locally advanced head and neck cancer, highlighting survival benefits and patient selection criteria.

Regulatory readiness Align business development efforts with the company’s ongoing regulatory roadmap and anticipated submissions, offering services or partnerships that support regulatory strategy, clinical commercialization, and market access planning.

Financial velocity Monitor and respond to fundraising activity and public offering timelines as signals for potential collaboration on late-stage trials, manufacturing scaling, and strategic investment discussions to de-risk and accelerate product adoption.